Trial · NCT05370235
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
NCT05370235, Phase 2, Unknown, Clinuvel Europe Limited
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V. Trials, record NCT05370235. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05370235
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
- NCT number
- NCT05370235
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 6 participants, estimated
- Lead sponsor
- Clinuvel Europe Limited
- Conditions
- Xeroderma Pigmentosum
- Interventions
- Afamelanotide
- First posted
- 2022-05-11
- Last updated
- 2023-09-21
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in minimal erythema dose (MED) in patients with XP-C. | From baseline to day 76. | MED is the lowest dose of UV light that causes reddening of the skin. |
| Primary | Change in MED in patients with XP-V. | From baseline to day 76. | MED is the lowest dose of UV light that causes reddening of the skin. |
| Secondary | Changes in UV-induced DNA damage, as assessed by quantification of UV photoproduct levels in patients with XP-C. | From baseline to day 76. | Analysis of UV photoproducts from skin samples. |
| Secondary | Changes in UV-induced DNA damage repair capacity, as assessed by quantification of DNA repair mechanisms in patients with XP-C. | From baseline to day 76. | Analysis of DNA repair mechanisms from skin samples. |
| Secondary | Changes in UV-induced DNA damage, as assessed by quantification of UV photoproduct levels in patients with XP-V. | From baseline to day 76. | Analysis of UV photoproducts from skin samples. |
| Secondary | Changes in UV-induced DNA damage repair capacity, as assessed by quantification of DNA repair mechanisms in patients with XP-V. | From baseline to day 76. | Analysis of DNA repair mechanisms from skin samples. |
| Secondary | Change in skin disease severity in patients with XP-C (A). | From baseline to day 76. | The higher the score, the more severe the disease. |
| Secondary | Change in skin disease severity in patients with XP-V (A) | From baseline to day 76. | The higher the score, the more severe the disease. |
| Secondary | Change in skin disease severity in patients with XP-C (B). | From baseline to day 76. | The higher the score, the more severe the disease. |
| Secondary | Change in skin disease severity in patients with XP-V (B). | From baseline to day 76. | The higher the score, the more severe the disease. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05370235
GET https://conductscience.org/api/trials/v1/NCT05370235/registered